MLA Diagnostics

MLA Diagnostics

A revolutionary prognostic test for early stage melanoma

Problem

Melanoma is the most deadly form of skin cancer. After diagnosis it is vital to know the risk of whether the disease is likely to spread. Prognostic information is important at this stage. Unfortunately current prognostic tools often classify patients as low risk but these patients still progress to metastatic disease and die without getting the treatment they needed.

Solution

MLA Diagnostics’ innovative product is an in vitro diagnostic (IVD) method that is able to determine melanoma patients with low or high metastatic risk. Performed by the pathologist, this test provides more insight on a patients’ expected outcome and will enable a different course of treatment (more or less intensive).

News from MLA Diagnostics

MIT R&D samenwerkings success; collaboration with Pathologie DNA begins

MLA Diagnostics is pleased to announce our success in gaining the MIT R&D samenwerkings project funding. We will collaborate with the top-level diagnostics specialists, -Pathologie

Egbert Smit December 23, 2020

Finalist in the Academic Startup Competition 2020

This month, MLA Diagnostics was selected as a finalist in the Academic Startup Competition 2020. 20 ground-breaking innovations in various fields were selected based on their

Egbert Smit October 2, 2020

NLC closes Momentum, provides funding support for MLA Diagnostics

NLC The European Healthtech Venture Builder has closed Momentum – a € 2.2 mln fund for private investments -within a month. This fund will be invested

Egbert Smit January 13, 2020

MLA Diagnostics is awarded a LBDF POP subsidy by LIOF

The LBDF POP grant will support a Health Technology Assessment project in collaboration with Clinical Epidemiology & Medical Technology Assessment (KEMTA) and HI-NL. The project consisted

Egbert Smit October 30, 2019

MLA Diagnostics receives EIT Headstart funding

MLA Diagnostics has recently received EIT funding from the Headstart program. With this funding the company will boost development the company’s Quality and Regulatory strategy.

Egbert Smit October 14, 2019

MLA Diagnostics receives a place in the MSD LAB1891 programme

LAB1891 and UtrechtInc will partner up to support 3 early stage startups selected by MSD to help innovation in their focus area. The programme provided coaching, workshops and

Egbert Smit August 16, 2019

Our Team

Dr. Egbert Smit, MBA

Prof. Dr. Manon van Engeland

Nikkie Buekers

Haley Baptist

Roland Zegger

Contact Us

Visit us in Maastricht

Where research and entrepreneurship come together